Pediatric relapsed/refractory ALK-positive anaplastic large cell lymphoma treatment and outcomes in the targeted-drug era
Lianna J. Marks(Stanford Medicine), Catherine Aftandilian(Stanford University), Kaitlin J. Devine(Children's Hospital of Philadelphia), Christopher J. Forlenza(Memorial Sloan Kettering Cancer Center), Joanna Weinstein(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), Kala Y. Kamdar(Baylor College of Medicine), Hilda Ding(University of California San Diego), Jennifer E. Agrusa(Baylor College of Medicine), Julie Rivers(Seattle Children's Hospital), Keith J. August(Children's Mercy Hospital), Prakash Satwani(Pediatrics and Genetics), Eric Lowe(St. Jude Children's Research Hospital), Matthew J. Ehrhardt(St. Jude Children's Research Hospital), Liora M. Schultz(Stanford Medicine), David J. Hoogstra(Michigan United), Charles Phillips(University of Tennessee at Knoxville), Carol Lin(Children's Hospital of Orange County), Keri Toner(Children's National), Zeinab Afify(Primary Children's Hospital), Rebecca Gardner(Seattle Children's Hospital), Jennifer A. Belsky(Indiana University School of Medicine), Victor Ritter, Chelsee Greer(Cook Children's Medical Center), Christine M. Smith(Vanderbilt University Medical Center), Michael P. Link(Stanford University), Anne F. Reilly(Children's Hospital of Philadelphia)
Cited by 9
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.
|Journal of Clinical Oncology|1996|920